文献速递脑血管病

他汀联合依折麦布双重治疗在「治疗卒中达标」试验中的获益

Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial.
PubMed 文献 · Stroke · 2022-09-26

这项TST试验的事后分析纳入2860例近3个月内缺血性卒中或近15天内短暂性脑缺血发作且伴脑血管或冠状动脉粥样硬化的患者,随机目标为LDL胆固醇<70或100±10 mg/dL。结果显示,较低目标组中接受他汀联合依折麦布双重治疗者主要血管事件风险降低(HR 0.60),而他汀单药治疗者未见降低(HR 0.92),颅内出血无显著增加。

要点

  • 较低目标组中双重治疗者主要血管事件风险降低(HR 0.60,95%CI 0.39-0.91,P=0.016)。
  • 他汀单药治疗者主要血管事件风险未见降低(HR 0.92,95%CI 0.70-1.20,P=0.52)。
  • 双重治疗与他汀单药治疗相比颅内出血无显著增加。

核心结论

  • 在TST试验中,以他汀联合依折麦布将LDL胆固醇降至<70 mg/dL,与100±10 mg/dL相比,持续降低后续卒中风险。

研究设计与样本

  • TST试验的事后分析,纳入2860例近3个月内缺血性卒中或近15天内短暂性脑缺血发作且伴脑血管或冠状动脉粥样硬化的患者。
  • 患者随机分配至LDL胆固醇目标<70或100±10 mg/dL,按需使用他汀和/或依折麦布。
  • 主要结局为缺血性卒中、心肌梗死、需紧急冠状动脉或颈动脉血运重建的新发症状及血管性死亡的复合终点。
  • 采用Cox回归模型,将降脂治疗作为时变变量,并校正随机策略、年龄、性别、索引事件(卒中或短暂性脑缺血发作)及距索引事件时间。

主要发现

  • 较低目标组中,接受双重治疗者基线LDL胆固醇高于他汀单药治疗者(141±38 vs 131±36,P<0.001)。
  • 双重治疗者和他汀单药治疗者达到的LDL胆固醇分别为66.2和64.1 mg/dL。
  • 双重治疗期间主要结局较更高目标组降低(HR 0.60,95%CI 0.39-0.91,P=0.016)。
  • 他汀单药治疗期间主要结局较更高目标组未见降低(HR 0.92,95%CI 0.70-1.20,P=0.52)。
  • 颅内出血无显著增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In atherosclerotic stroke, lipid-lowering treatment with a target LDL (low-density lipoprotein) cholesterol of <70 compared with 100±10 mg/dL reduced the risk of subsequent cardiovascular events. This post hoc analysis explored the relative effects of the combination of statin and ezetimibe (dual therapy) and statin monotherapy in achieving the lower LDL cholesterol target and in reducing the risk of major vascular events, as compared with the higher target group. METHODS: Patients with ischemic stroke in the previous 3 months or transient ischemic attack within the previous 15 days and evidence of cerebrovascular or coronary artery atherosclerosis were randomly assigned to a target LDL cholesterol of <70 or 100±10 mg/dL, using statin and/or ezetimibe as needed. The primary outcome was the composite of ischemic stroke, myocardial infarction, new symptoms requiring urgent coronary or carotid revascularization, and vascular death. Cox regression model including lipid-lowering therapy as a time varying variable, after adjustment for randomization strategy, age, sex, index event (stroke or transient ischemic attack), and time since the index event. RESULTS: Among 2860 patients enrolled, patients who were on dual therapy during the trial in the lower target group had a higher baseline LDL cholesterol as compared to patients on statin monotherapy (141±38 versus 131±36, respectively, P<0.001). In patients on dual therapy and on statin monotherapy, the achieved LDL cholesterol was 66.2 and 64.1 mg/dL respectively, and the primary outcome was reduced during dual therapy as compared with the higher target group (HR, 0.60 [95% CI, 0.39-0.91]; P=0.016) but not during statin monotherapy (HR, 0.92 [95% CI, 0.70-1.20]; P=0.52), with no significant increase in intracranial bleeding. CONCLUSIONS: In the TST trial (Treat Stroke to Target), targeting an LDL cholesterol of < 70 mg/dL with a combination of statin and ezetimibe compared with 100±10 mg/dL consistently reduced the risk of subsequent stroke. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Amarenco P, Kim JS, Labreuche J, et al. Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial. Stroke. 2022. PMID: 36154103. doi:10.1161/STROKEAHA.122.039728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。